Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Therapeutic Apheresis and Dialysis is Scopus-indexed (Q2, CiteScore 3), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by John Wiley and Sons Inc.
Checked against the index lists dated .
ISSN 1744-9979Verify ISSN ↗1744-9987Verify ISSN ↗
Publisher: John Wiley and Sons Inc
Cost to publish: About US$3,350 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Nephrology | 41 / 88 | 53rd | Q2 |
| Hematology | 78 / 151 | 48th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2003–present, best quartile Q2, CiteScore 3.
Therapeutic Apheresis and Dialysis is Q2 in Nephrology (rank 41 of 88) and Q3 in Hematology (rank 78 of 151), by CiteScore 2025.
Therapeutic Apheresis and Dialysis is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3, which places it in quartile Q2 at the 53rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.453, quartile Q3, with an H-index of 65.
The publisher lists an article processing charge of about US$3,350 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Therapeutic Apheresis and Dialysis is published by John Wiley and Sons Inc. Its print ISSN is 1744-9979 and its online ISSN is 1744-9987.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Therapeutic Apheresis and Dialysis has an h-index of 71 and a 2-year mean of 1.1 citations per paper (OpenAlex). Its Scopus CiteScore is 3, quartile Q2. On 2-year citations it ranks #50 of 87 Scopus journals in Nephrology.
Therapeutic Apheresis and Dialysis published 150 papers in 2025; its busiest recent year was 2022 with 188. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 89 research articles (2026), authors are most often from Japan (41.9%), China (16.9%) and Türkiye (14%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 5 retracted papers are recorded (1.3 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.